Monoclonal antibodies against RGM A protein for use in treatment of retinal nerve fiber layer degeneration

The present invention relates to monoclonal antibodies directed against RGM A protein for use in the treatment of retinal nerve fiber layer degeneration. The present application describes RGM A binding proteins, in particular monoclonal antibodies, and in particular CDR transplanted, humanized forms thereof, for use in the treatment of retinal nerve fibrous layer (RNFL) degeneration, which have the ability to bind to RGM A and to prevent binding of RGM proteins to RGM A receptors and other RGM A binding proteins, and thus neutralize the function of RGM A. The present invention further describes a method of treating a mammal in therapy or prophylaxis against RNFL degeneration. 本发明涉及用于在视网膜神经纤维层变性治疗中使用的针对RGM A蛋白质的单克隆抗体。本申请描述了用于在视网膜神经纤维层(RNFL)变性治疗中使用的RGM A结合蛋白，特别是单克隆抗体，且特别是其CDR移植、人源化形式，其具有与RGM A结合且阻止RGM蛋白质与RGM A受体和其他RGM A结合蛋白结合的能力，并且因此中和RGM A的功能，以及描述了针对RNFL变性在治疗或预防上治疗哺乳动物的方法。